Parkinson’s Diseases: World Drug Industry and Market 2016-2026 – our new study reveals trends, R&D progress, and predicted revenues Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions: • How is the Parkinson’s disease therapeutics market evolving? • What is driving and restraining the Parkinson’s disease therapeutics market? • How will political and regulatory factors influence the regional markets and submarkets? • Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period? • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
Forecasts from 2016-2026 and other analyses show you commercial prospects Our new report provides quantitative analyses to answer these key questions: • What are the market shares of the Parkinson’s therapeutics disease market in 2015? • How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026? • What Parkinson’s disease drugs are in the development pipeline? • How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026? • How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales.
Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.
Discover sales predictions for the world market and submarkets Discover in our report overall world revenue to 2026 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2026 for five therapeutic submarkets at world level: • Dopaminergic Agents • Dopamine Receptor Agonists • MAO-inhibitors • COMT-inhibitors • Other Therapeutic Options
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for Parkinson’s disease drugs How will individual medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of three brands sold by four companies: • Neupro (UCB) • Azilect (Teva) • Azilect (Lundbeck) • Comtan/Stalevo (Novartis)
What are the prospects in the leading regions and countries? Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015.
Our work also shows individual revenue forecasts to 2026 for 11 national markets: • United States (US) • Japan • EU leaders – Germany, France, the UK, Italy and Spain (EU5) • BRIC nations – Brazil, Russia, India and China
Leading companies and potential for market growth In 2015 the overall world PD drug market generated $3217m. Visiongain predicts its revenues in 2020 to reach $3472m. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector: • Novartis • Teva • UCB • Roche • Lundbeck
What affects producers of those medicines? Our report discusses issues and events affecting that industry and market from 2015, including these: • Research and development (R&D) – drugs, diagnostic tests, and related technologies • Disease prevalence – expanding patient populations • Disease-modifying drugs and obstacles to cures • Regulatory guidelines – changes and opportunities. • Drugs and related technologies to transform the market • Biomarkers • Deep brain stimulation (functional neuromodulation) • Intellectual property (IP), licensing agreements and partnerships.
Our 172-page report provides 120 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis: • Revenues for Parkinson’s disease treatments to 2026 – assess that overall world drugs market’s potential and get forecasted revenues for the five leading sub-classes: dopaminergic agents, dopamine receptor agonists, COMT- and MAO-inhibitors and other therapeutic options. • Products’ sales to 2026 – discover predicted revenues Neupro, Comtan/Stalevo, and Azilect and see how those medicines can compete and succeed • National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth • R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities • Companies, news and opinions – examine participants, including Roche, Novartis, UCB and Lundbeck and get two exclusive interviews, helping your reputation for insight and staying ahead. Visiongain interviewed: – Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US – Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York. • Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of Findings: World Market Overview 2015 to 2026 1.2 Why You Should Read This Report 1.3 How This Report Delivers: Chapter Outlines 1.4 Main Questions Answered by This Analysis 1.5 Who is This Study For? 1.6 Research and Analysis Methods 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. Introduction to Parkinson’s Disease and its Treatments 2.1 What Causes Parkinson’s? 2.2 Motor Symptoms of Parkinson’s Disease 2.2.1 Tremor: The First Sign of PD 2.2.2 Uncontrolled Muscle Contractions Cause Rigidity 2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s 2.2.4 Postural Instability Manifests as PD Progresses 2.3 Neuropsychiatric Symptoms are Common in PD Patients 2.3.1 Behavioural Deficits are Often the Most Widespread 2.3.2 Cognitive Impairment can Impede Daily Tasks 2.3.3 Autonomic Dysfunction: Another Common Occurrence 2.4 Other Symptoms Associated with Parkinson’s 2.5 Parkinson’s Disease: Diagnosis and Treatment 2.5.1 Diagnosis is Difficult 2.5.2 Treatment Options – Therapeutic Classes
3. Parkinson’s Disease: World Drugs Market, 2016-2026 3.1 Sales of the Overall World PD Drugs Market, 2015-2026 3.2 Parkinson’s Disease: Market Segmentation, 2015 3.3 Overall PD Drug Market: Commercial Drivers and Restraints 3.4 Dopaminergic Agents: Foundation of PD Treatment 3.4.1 Levodopa Therapy 3.4.2 Patent Expiries Affect the Market 3.4.3 New Levodopa Therapies on the Horizon 3.4.4 Dopaminergic Agents: Market Projections to 2026 3.5 Dopamine Receptor Agonists: The Leading Class in 2016 3.5.1 Dopamine Agonists: A Front Line Drug 3.5.2 Advantages over L-Dopa Therapy 3.5.3 Leading Drugs in the Segment 3.5.4 A Healthy R&D Pipeline 3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026 3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment 3.6.1 Entacapone: The Leading Drug in this Segment 3.6.2 Commercial Scope for COMT Inhibitors 3.6.3 COMT Inhibitors: Market Projections, 2016-2026 3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT? 3.7.1 MAO-B Inhibitor Therapeutics in the Market 3.7.2 New MAO-B Products in Development 3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026 3.7.4 Other Therapeutic Options: A Growing Opportunity 3.7.5 Generic Erosion in the PD Market 3.7.6 A Broad and Diverse Pharmaceutical Segment 3.7.7 Other Non-medication PD Therapies 3.7.8 The Pipeline Offers Disease Modifying Potential 3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026
4. Leading Companies in the PD Drug Market, 2016 4.1 PD: Novartis sales of Stalevo/Comtan 4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026 4.2 Teva’s Azilect: Past, Present and Future 4.2.1 Market Forecast for Azilect, 2015-2026 4.3 UCB’s Leading Neupro Patch Drug 4.3.1 Market Forecast for Neupro, 2016-2026 4.4 Other Market Players
5. The Leading National Markets, 2016-2026 5.1 Regional Breakdown of the World PD Drug Market, 2016 5.2 The World PD Drug Market: Regional Forecasts to 2026 5.3 The PD Drug Market in the US: The Largest Single National Market 5.3.1 Market Projections for the US, 2015-2026 5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026 5.4.1 Market Projections for the EU5, 2016-2026 5.4.2 EU5 Breakdown by Country, 2016 5.4.3 Market Projection for EU5 Countries, Regional Breakdown 5.4.4 Germany: The Largest EU5 Market 5.4.5 France: Strong Healthcare System – What’s Possible There? 5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market 5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales? 5.4.8 The PD Drug Market in Italy: Rising and Ageing Population 5.5 Japan has the Highest Proportion of Over-65s in the World 5.5.1 Predictions for Japanese PD Drug Market, 2016-2026 5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC) 5.6.1 Breakdown of BRIC Revenues by Country, 2016 5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2016-2026 5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future? 5.6.4 Russia’s Healthcare Market Gives Generic Sales Opportunities 5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market 5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines
6. Research and Development for Treating Parkinson’s Disease 6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline 6.2 Growing Potential of Marketed Products: Phase IV Studies 6.3 Phase III Clinical Products Promising Potential in the PD market 6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa 6.3.2 Newron’s Safinamide Expected Launch in 2020 6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis 6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist 6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist 6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG) 6.3.7 Can Opicapone Compete with Existing COMT Inhibitors 6.3.8 Pitolisant: Addressing an Unmet Need 6.3.9 Northera: Oral Precursor of Norepinephrine 6.3.10 Targin by Mundipharm 6.3.11 Nurelinfor Levodopa-Induced Dyskinesia 6.3.12 SYN-115/120: Superior to Istradefylline? 6.4 Phase II PD Pipeline: Overview 6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates 6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist 6.4.3 CVT-301: A Novel Intrapulmonary Approach 6.4.4 DM-1992: Can Compete with Levodopa Reformulations? 6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma 6.4.6 Orient Addresses Sialorrhoea 6.4.7 NH004: Formulated with a Muco-Adhesive Property 6.4.8 VR040: A Reformulation of Apomorphine 6.4.9 AVP-923: A Novel Approach for LID-PD 6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101 6.4.11 News for NeuroDerm’s Reformulations 6.5 Phase I and Pre-clinical PD Pipeline: Overview 6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa 6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation 6.5.3 UCL Show Exenatide Potential in Parkinson’s 6.5.4 Titan Pharmaceuticals Develop a Novel Platform 6.6 Neuroprotective Drugs Offer Hope 6.6.1 Phytopharm and Cogane Development 6.6.2 The Potential of Dietary Supplements 6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s 6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s 6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment 6.6.6 Antibody Targeting: The Coming of Age 6.7 Gene Therapy: Promising Research and Technology 6.7.1 ProSavin: Leading Gene Therapy Product 6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons 6.7.3 AAV-hAADC-2: Another Gene Therapy Contender 6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology
7. Qualitative Analysis of the PD Drug Market, 2016 7.1 SWOT Analysis of the PD Market 7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016 7.1.2 Opportunities and Threats There from 2016 Onwards 7.2 STEP Analysis of the PD Market 7.2.1 Social Implication of Living with PD 7.2.2 Technological Developments on the Horizon 7.2.3 Economic Pressures: Healthcare Budgeting 7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways
8. Research Interviews 8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US 8.1.1 The Overall PD Market 8.1.2 Current Understanding of Stem Cell Therapy 8.1.3 ISCO’s Novel PD Programme 8.1.4 The Potential of Immune-Matching 8.1.5 The Controversy Surrounding Stem Cell Research 8.1.6 The Potential for Parthenogenesis in PD and Other Applications 8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York 8.2.1 A possible Cure 8.2.2 Future Potential: Research
9. Conclusions from the Research and Analysis 9.1 The World PD Market: Predictions to 2026 9.2 Which Therapeutic Class will Dominate the Market in 2026? 9.3 Disease Modification: The Ultimate Goal 9.4 The Future of the Industry and Market for Parkinson’s Medicines
Some Associated Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 1.1 Global Parkinson’s disease Market Segmentation Overview, 2015 Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2016 Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2015-2026 Figure 3.4 PD Drug Market, Drivers and Restraints, 2015-2026 Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2015-2026 Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2016-2026 Figure 3.7 Dopaminergic Receptor Agonists Segment Forecast, Revenues ($m), 2015-2026 Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2015-2026 Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2015-2026 Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2015-2026 Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2015-2026 Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2016-2026 Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2015-2026 Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2015-2026 Figure 4.1 Revenues ($m) of Parkinson’s Drugs by Leading Company, 2013-2015 Figure 4.2 Orion’s Comtan/Stalevo Drug Revenues ($m) Forecast, 2014-2026 Figure 4.3 Teva’s Azilect Drug Revenues Forecast, 2014-2026 Figure 4.3.1 Lundbeck’s Azilect Drug Revenues Forecast, 2014-2026 Figure 5.1 PD Market Breakdown by Region, Market Shares (%), 2016 Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2026 Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2015-2026 Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2015-2026 Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2015-2026 Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share(%), 2016 Figure 5.7EU5 Regional Breakdown by Country, Revenues ($m), 2015-2026 Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2015-2026 Figure 5.9 German PD Drug Market, Revenues ($m), 2015-2026 Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2015-2026 Figure 5.11 French PD Drug Market, Revenues ($m), 2015-2026 Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2015-2026 Figure 5.13 UK PD Drug Market, Revenues ($m), 2015-2026 Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2015-2026 Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2015-2026 Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2015-2026 Figure 5.17 Italian PD Drug Market, Revenues ($m), 2015-2026 Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2015-2026 Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2015-2026 Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2015-2026 Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), BRIC Market Share (%), 2016 Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2015-2026 Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2015-2026 Figure 5.24 Russian PD Drug Market, Revenues ($m), 2015-2026 Figure 5.25 Indian PD Drug Market, Revenues ($m), 2015-2026 Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2015-2026 Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA genes, which Reduces Immune Rejection Figure 9.1 PD Drug Market, Overall Revenues ($m), 2015, 2020 and 2026 Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2015, 2020 and 2026
Abbott Laboratories AbbVie Pharmaceuticals Acadia Pharmaceuticals Adamas Pharmaceuticals Addex Therapeutics Amgen Amicus Therapeutics AmarantusBioSciences Amylin Pharmaceuticals Ark Therapeutics AstraZeneca Avanir Pharmaceuticals AxxonisPharma BIAL - Portela BiogenIdec Bioprojet Pharma Biotie Therapies Biovail BoehringerIngelheim Cardiovascular and Renal Drug Advisory Committee Ceregene Chelsea Therapeutics Civitas Therapeutics Columbia University Dainippon Sumitomo Pharma Depomed DiaGenic Domain Therapeutics Dr. Reddy’sLaboratories Durin Technologies Eisai European Medicines Agency (EMEA/EMA) Food and Drug Administration (US FDA) Genzyme GlaxoSmithKline (GSK) ImpaxLaboratories Intec Pharma International Stem Cell Corporation Ipsen JuvantiaPharma Kyowa Hakko Kirin Lundbeck Meiji Seika Merck & Co. Merck Serono Mundipharma Research Mylan Napp Pharmaceuticals National Health Service (NHS, UK) National Institute for Health and Clinical Excellence (NICE, UK) National Institute of Neurological Disorders and Stroke (NINDS, US) National Institutes of Health (NIH, US) Neuren Pharmaceuticals Neuroderm NeuroGeneration NeuroHealing Neurologix Newron Pharmaceuticals Novartis NuroPro Ono Pharmaceuticals Orient Pharma Orion Otsuka Pharmaceuticals Oxford BioMedica Parkinson’s UK Par Pharmaceuticals Pfizer Pharmaceutical Research and Manufacturers Association Phytopharm Power3 Medical Products Prothena Corporation Roche Roxane Laboratories Sanofi Santhera Schering Plough Sheffield Institute for Translational Neuroscience SK Biosciences Skye Pharma Sun Pharmaceuticals Technion-Israel Institute of Technology Teva Pharmaceutical Industries The Michael J. Fox Foundation The Parkinson Study Group Titan Pharmaceuticals UCB uniQure University at Buffalo, the State University of New York University College London (UCL) Valeant Varinel Vectura Group Vernalis Watson Pharmaceuticals Wockhardt XenoPort Zambon Group
Download sample pages
Complete the form below to download your free sample pages for Parkinson’s Diseases: World Drug Industry and Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Parkinson’s Diseases: World Drug Industry and Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
